Clinical use of recombinant human luteinizing hormone beyond hypogonadotropic hypogonadism: a multicenter descriptive analysis from five Italian fertility centers

Abstract Background Recombinant human luteinizing hormone (rLH) was originally introduced to supplement recombinant human follicle-stimulating hormone (rFSH) for controlled ovarian stimulation (COS) in patients with hypogonadotropic hypogonadism. Promising evidence is emerging regarding the efficacy...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Andrea Busnelli, Paolo Emanuele Levi-Setti, Valeria Stella Vanni, Andrea Carosso, Gianluca Gennarelli, Ilario Candeloro, Francesco Maria Fusi, Anna Elisa Nicolosi, Rossella Masciangelo, Andrea De Rosa, Letizia Li Piani, Chiara Dallagiovanna, Marco Reschini
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2026-05-01
Saila:	Reproductive Biology and Endocrinology
Gaiak:	In-vitro fertilization Recombinant LH Recombinant FSH LH supplementation Hypogonadotropic hypogonadism Poor ovarian responders
Sarrera elektronikoa:	https://doi.org/10.1186/s12958-026-01551-y
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!